Colon Cancer Cell Pathway is Identified
Posted on: Tuesday, 20 February 2007, 12:00 CST
U.S. geneticists have identified a cell pathway that plays a critical role in the development of colon cancer.
Case Western Reserve University scientists, led by Assistant Professor Zhenghe John Wang, say the pathway might also play a role in the development of lung and stomach cancers.
Investigators identified STAT3 -- signal transducer and activator of transcription 3 -- as a target regulated by the receptor protein tyrosine phosphatase T that was previously identified to be mutated in colon, lung and stomach cancer patients.
Our study shows that receptor protein tyrosine phosphatase T regulates an important signaling pathway that is critical in cancer development, said Wang. This identification will allow new approaches to pharmacological designs and facilitate alternative approaches for cancer treatment.
With more than 52,000 deaths annually, colon and rectal cancer is the second leading cause of cancer death in the United States.
The study -- which included collaboration with Bert Vogelstein, Victor Velculescu and Kenneth Kinzler of the Johns Hopkins Kimmel Cancer Center and a team led by Roberto Polakiewicz at Cell Signaling Technology Inc. -- appears in the online early edition of the Proceedings of the National Academy of Sciences.
Source: United Press International
Related Articles
- Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
- Intrinsic Bioprobes, Inc. Enters into a $1.27M Contract with the National Cancer Institute to Develop Multiplex Mass Spectrometric Immunoassays for Detection of Low Abundance Cancer-Related Proteins
- NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
- New Cancer Diagnostic Tool Developed
- Clinical Trial Results From Cancer Vaccine Being Developed By Generex Biotechnology Subsidiary to Be Presented at San Antonio Breast Cancer Symposium
- Curis, Inc. Augments Scientific Advisory Board With Leaders in Cancer Research and Development
- Last Chance for Breakthrough Cancer Research Developments: 8th Annual Anti-Cancer Drug Discovery & Development Summit, July 17-18, 2006
- AKT cancer cell pathway demonstrates unexpected function
- Keep Up-to-Date on the Progress of the Most Pronounced Anti-Cancer Drugs in Development for Breast Cancer Treatment
 |
 |
User Comments (0)
RSS Feeds